OBSEF Projected Dividend Yield

Act Nom/ObsEva SA ( OTCBB : OBSEF )

ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for woman's reproductive health and pregnancy. Co.'s portfolio includes: Linzagolix, which is an oral gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis in pre-menopausal women; Ebopiprant, which is an oral selective prostaglandin F2a, receptor antagonist, treatment for preterm labor; and Nolasiban, which improves clinical pregnancy and live birth rates in women undergoing embryo transfer following an in-vitro fertilization cycle.

20 YEAR PERFORMANCE RESULTS